Business Wire

KENUP-FOUNDATION

Share
CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention

Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden.

CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is to assess if the antibody can prevent HIV infection in humans as effectively as it does in monkeys. If shown to be effective in preventing HIV, the antibody, in conjunction with the VRC’s VRC07 antibody, has the potential to break the HIV infection cycle. However, the difficulties in manufacturing the antibody have been an obstacle in the research and development of CAP256. These obstacles can be overcome and the production of this antibody can be markedly improved.

Mediated by kENUP Foundation, Evotec SE intends to enter into a long-term collaboration with CAPRISA to further optimize and develop CAP256, using innovative approaches they have developed and used successfully with other antibodies. The collaboration will leverage the capabilities at Just – Evotec Biologics in optimizing manufacturing processes through artificial intelligence and machine learning. The result is a more productive manufacturing process for lower cost and wider access for the product. Evotec’s centers of excellence in Redmond (US) and Toulouse (France) will play a key role for enhancing the antibody’s production, facilitating co-formulation of the CAP256-VRC07 combination and manufacturing CAP256 for clinical trials. CAPRISA is conducting clinical trials of these antibodies in conjunction with the Center for Infectious Diseases Research in Zambia, with the support of the European Union – Developing Countries Clinical Trial Partnership.

In the presence of Hon. Dr Daniel Ngamije, Minister of Health of the Republic of Rwanda, Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa, and Antoine Anfré, French Ambassador to the Republic of Rwanda, the participants of the AU-EU Ministerial Meeting discussed the project’s potential impact on resilience and independence of African health systems.

Prof Salim Abdool Karim , Director of CAPRISA: “We are excited to work with Evotec and the VRC in this project to improve the CAP256 manufacturing processes. It is the culmination of a decade of research to develop CAP256 in order to assess whether this antibody, which originated in Africa, is effective for preventing HIV in Africa.”

Dr Werner Lanthaler , Chief Executive Officer of Evotec SE: “We look forward to collaborate on re-engineering CAP256. We will use and build global capacities to maximize impact for this important product. This is core of our mission to maximize access to modern biologics also in Africa.”

Hon. Dr Daniel Ngamije , Minister of Health, Republic of Rwanda: “Rwanda is focused on creating a biopharmaceutical ecosystem. With the work of CAPRISA and Evotec on monoclonal antibodies, we have the potential to finally ensure Africa’s access to highly effective therapeutics for many diseases endemic to our continent. This effort has Rwanda’s full support.”

About Evotec

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

About CAPRISA

CAPRISA is a world-leading AIDS research centre based in Africa. It is renowned for its research that showed that high rates of HIV in Africa are driven by “The Cycle of HIV Transmission” where young women partner with men about 10 years older. CAPRISA provided the first evidence that topical antiretrovirals prevent HIV infection. It has since been leading the development of several new HIV prevention technologies in Africa. The five major partner institutions that constitute CAPRISA are: University of KwaZulu-Natal, University of Cape Town, University of the Western Cape, National Institute for Communicable Diseases and Columbia University in New York. CAPRISA has diverse expertise in basic and molecular epidemiology, virology, immunology, infectious disease medicine, bioinformatics, statistics, ethics and health policy. CAPRISA is headquartered at the Nelson R Mandela Medical School at the University of KwaZulu-Natal in Durban, South Africa.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi

$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release

MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered

Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release

With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor

With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release

Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C

IEEE Standards Commitment to Advancing AI Governance Includes Impactful Contributions to New International AI Standards Exchange11.7.2025 08:00:00 CEST | Press release

IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and its IEEE Standards Association (IEEE SA) announced today that its portfolio of over 100 global AI-related standards is included in the new International AI Standards Exchange. This Exchange is a centralized repository of international AI standards with the aim to foster collaboration and responsible AI development worldwide. IEEE and its AI global standards were recognized in the 2024 United Nations AI Advisory Body’s Report, Governing AI for Humanity, which created the impetus for the AI Standards Exchange. Due to its impactful AI standards and related work, IEEE, a major standards body, was included as a partner in the establishment of the Exchange. IEEE President and CEO Kathleen Kramer, who is speaking at the AI for Good Summit this year at the High-Level AI Standards Panel,shares, “IEEE’s mission of advancing technology for the benefit of humanity is foundational to ou

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye